Schechter Investment Advisors LLC Has $446,000 Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Schechter Investment Advisors LLC lifted its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 383.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,247 shares of the company’s stock after purchasing an additional 22,401 shares during the period. Schechter Investment Advisors LLC’s holdings in Dr. Reddy’s Laboratories were worth $446,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC raised its holdings in Dr. Reddy’s Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after acquiring an additional 137 shares during the period. Van ECK Associates Corp raised its holdings in Dr. Reddy’s Laboratories by 64.3% in the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after acquiring an additional 322 shares during the period. Lifestyle Asset Management Inc. raised its holdings in Dr. Reddy’s Laboratories by 3.2% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 13,689 shares of the company’s stock worth $1,088,000 after acquiring an additional 422 shares during the period. Natixis Advisors LLC raised its holdings in Dr. Reddy’s Laboratories by 7.2% in the 3rd quarter. Natixis Advisors LLC now owns 10,937 shares of the company’s stock worth $869,000 after acquiring an additional 735 shares during the period. Finally, Venturi Wealth Management LLC bought a new position in Dr. Reddy’s Laboratories in the 3rd quarter worth $60,000. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Performance

NYSE:RDY opened at $12.92 on Thursday. The firm’s 50-day moving average is $14.34 and its 200-day moving average is $15.00. Dr. Reddy’s Laboratories Limited has a 52-week low of $12.62 and a 52-week high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The company has a market cap of $10.78 billion, a price-to-earnings ratio of 20.57 and a beta of 0.50.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Equities research analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on RDY. Barclays dropped their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. Finally, StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.